Poseida Therapeutics Inc Ordinary Shares PSTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
-
Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
-
Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
-
Poseida Therapeutics to Present at Upcoming Investor Conferences
-
Poseida Rises After Reporting Smaller-Than-Seen Loss, Partnership Progress
-
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024
-
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
-
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
Trading Information
- Previous Close Price
- $3.00
- Day Range
- $2.96–3.10
- 52-Week Range
- $1.83–4.27
- Bid/Ask
- $2.83 / $3.19
- Market Cap
- $288.49 Mil
- Volume/Avg
- 408,147 / 445,866
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 337
- Website
- https://www.poseida.com
Comparables
Valuation
|
Metric
|
PSTX
|
ARTV
|
MGNX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.74 | — | 3.30 |
Price/Sales | 3.20 | 3.69 | 4.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
PSTX
ARTV
MGNX
Financial Strength
|
Metric
|
PSTX
|
ARTV
|
MGNX
|
|---|---|---|---|
Quick Ratio | 2.44 | 4.43 | 2.53 |
Current Ratio | 2.48 | 4.59 | 2.71 |
Interest Coverage | −11.50 | — | −128.87 |
Quick Ratio
PSTX
ARTV
MGNX
Profitability
|
Metric
|
PSTX
|
ARTV
|
MGNX
|
|---|---|---|---|
Return on Assets (Normalized) | −33.29% | −16.21% | −59.21% |
Return on Equity (Normalized) | −92.95% | — | −120.96% |
Return on Invested Capital (Normalized) | −46.70% | — | −102.88% |
Return on Assets
PSTX
ARTV
MGNX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zpcftwgtm | Fnjw | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Tcclfhcc | Xvmzqtx | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Mywtjnvh | Hsrvvhw | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qgmdrjflj | Qqnkl | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Qzpxmsc | Dhs | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Jqjwsmqdf | Jcc | $28.0 Bil | |||
| Moderna Inc
MRNA
| Pbmgqwhfm | Hqsq | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Lpyzkxp | Krqq | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cdmyymrt | Ngpglkg | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mkpqlkzz | Ccxvqfh | $12.6 Bil |
United States